VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of EUR10.2M secured by commitments amounting to 76.6%

DJ VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of EUR10.2M secured by commitments amounting to 76.6%

VALBIOTIS SA 
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of EUR10.2M secured 
by commitments amounting to 76.6% 
08-Jun-2026 / 08:00 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
=---------------------------------------------------------------------------------------------------------------------- 
Valbiotis announces the launch of a capital increase with maintained PSR in the amount of EUR10.2M secured by commitments 
of up to 76.6% 
  
 . Capital increase with maintained preferential subscription rights ("PSR") in the amount of EUR10.2M 
 
 . The offering is secured up to 76.6% through:   
 . A subscription commitment of EUR2.0M from Tao Xianhua, Aika Co-Founder & CEO (through his holding company 
  Ximen RD PTE Ltd), who holds a 51% stake in the China-based joint venture alongside Valbiotis 
 . Guarantee commitments amounting to EUR5.8M  
 . Subscription Price: EUR0.86 per share, i.e., a discount of 19.9% compared to the weighted average share 
  price over the three trading sessions preceding the determination of the price (namely June 3, 4 & 5, 2026) and a 
  discount of 9.8% compared with the theoretical value of the share after detachment of the rights 
 . Subscription Parity: 1 new share for every 2 existing shares 
 . Detachment of preferential subscription rights on June 10, 2026 
 . Trading period for preferential subscription rights from June 10, 2026 to June 22, 2026 
 . Subscription period for new shares open from June 12, 2026 to June 24, 2026 
 . Securities eligible for FIP, FCPI, PEA and PEA PME-ETI, 150-0-B-Ter Re-investment/Sale IR-PME   
Join the webinar presenting the initiative on Monday, June 15, 2026, at 6 p.m. 
Click here to register 
La Rochelle, June 8, 2026 (8:00 a.m. CEST) - Valbiotis (FR0013254851 - ALVAL, PEA/SME eligible), a French laboratory 
specializing in the development and distribution of scientifically tested nutritional solutions designed to prevent 
cardio-metabolic imbalances and address everyday health challenges, announces the launch of a capital increase with 
maintained preferential subscription rights intended to finance the acceleration of its commercial development in 
France and internationally. 
  
Sébastien Peltier, CEO and Co-Founder of Valbiotis, states: "More than ten years ago, we made the strategic decision to 
build a new generation of dietary supplements on an unrivaled clinical foundation - now comprising 13 proprietary 
studies and more than 1,500 subjects evaluated - to address cardio-metabolic disorders, which are now at the forefront 
of public health policy. Our commercial rollout in France has shown strong momentum: in just sixteen months, our 
pharmacy footprint has doubled (559 as of the end of April 2026), average order value has more than tripled, and our 
e-commerce channel has recorded a 33% increase in customers over the past four months. Several growth drivers are 
expected to further accelerate this momentum: the expansion of our product portfolio, the multiplication of 
partnerships with pharmacy groups - providing privileged access to more than 4,700 pharmacies - and the strengthening 
of our network in the field, which is expected to comprise 25 Medical Promotion Officers by 2027. Beyond France, 
Valbiotis is actively expanding internationally through two strategic partnerships in Asia and the Middle East, both 
expected to begin generating revenue as of 2026. The participation of Tao Xianhua, Co-Founder and CEO of Aika, (which 
holds a 51% stake in our Chinese joint venture), in this capital increase constitutes a strong vote of confidence and 
reinforces our ambition to build a leading Asian player in dietary supplements targeting cardio-metabolic imbalances. 
Against this backdrop of strong acceleration, we are launching this capital increase, which is open to all investors 
while preserving preferential subscription rights for existing shareholders. I hope that this offering will attract the 
support of a large number of investors who wish to participate in and contribute to Valbiotis' ambitions."  
Tao Xianhua (Aika Cofounder & CEO): "Over the past six months, I have been working closely with Sébastien Peltier's 
team to build our partnership, which will soon lead to the commercial launch of Valbiotis products tailored to Asian 
consumers." This collaboration has enabled me to fully appreciate the company's potential and the strength of what sets 
it apart: a rare commitment to scientific rigor and unrivaled expertise in plant science. It was this conviction that 
led me to want to become an active shareholder in Valbiotis. I am confident that Valbiotis will establish itself as a 
key player in the dietary supplements market, addressing cardio-metabolic imbalances." 
BACKGROUND FOR THE OFFERING 
Founded in 2014, Valbiotis is a French laboratory specializing in the development and distribution of scientifically 
validated first-line nutritional solutions designed to prevent cardio-metabolic imbalances. Through an innovative 
approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis develops 
high-quality formulations based on patented active ingredients validated by rigorous clinical studies, designed to 
provide long-term support for cardio-metabolic health and address associated functional issues such as sleep, fatigue, 
mood management, immunity and vitality. 
Valbiotis has successfully transitioned from an R&D-focused company to a commercial model. The laboratory currently 
develops two ranges of dietary supplements:  
 . The Valbiotis^PRO range, comprising four dietary supplements backed by robust scientific evidence, 
  unrivaled on the market, which address the risk factors for cardiometabolic health issues:  Metabolic Health 
  (TOTUM.63), Cholesterol (Lipidrive^), Cardio-Circulation (Tensodrive^, formerly TOTUM.854) and the management of 
  NAFLD (Chronic liver disease) (Steadrive^, formerly TOTUM.448, which is currently in the clinical development 
  phase and not yet on the market); and  
 . The Valbiotis^PLUS range, currently comprising 8 dietary supplements designed to address the symptoms 
  associated with cardio-metabolic imbalances, as well as various everyday health issues. These products are 
  formulated on the basis of data from the scientific literature. 
In just under a year, the Company has succeeded in building up significant commercial momentum in France through a 
multi-channel marketing strategy comprising: 
 . An e-commerce site whose traffic has led to a significant increase in the number of customers (from 948 
  at the end of 2024, to 4,030 at the end of 2025, and 5,351 by the end of April 2026), with the average order value 
  rising from EUR71 in 2024, to EUR86 at the end of 2025, and reaching EUR91 by the end of April 2026; 
 . A network of 559 pharmacies at the end of April 2026, supported by an in-house sales force comprising a 
  team of 16 Medical Promotion Officers and 1 Key Accounts Manager. 
At the same time, the Company began its international expansion at the end of 2025, marked by the following key 
milestones: 
 . November 2025: The signing of a strategic agreement with the Chinese group AIKA, involving the creation 
  of a Chinese joint venture in which Valbiotis holds a 49% stake (with the AIKA group holding 51%). This joint 
  venture is dedicated to marketing Valbiotis products in key Asian markets: China, Hong Kong, Japan, Taiwan, Macao, 
  Singapore, Vietnam and Indonesia, with the possibility of expanding the partnership into other countries: South 
  Korea, the Philippines, Malaysia, Brunei, Laos, Cambodia, Thailand (http://investisseurs.valbiotis.com/wp-content/ 
  uploads/2025/11/25-1117-CP-Valbiotis-Asie-VDEF-FR-03.pdf); 
 . January 2026: The signing of an exclusive distribution agreement for the Middle East (Saudi Arabia, 
  Lebanon and Iraq) with Mena Nutrition (http://investisseurs.valbiotis.com/wp-content/uploads/2026/01/ 
  CP-MoyenOrient_080126-FR.pdf); 
 . March 2026: The launch of operations in Asia, with a joint venture now fully operational and set to begin 
  marketing Valbiotis products in mainland China and Hong Kong via the cross-border e-commerce (CBEC) channel, thanks 
  to partnerships already in place with leading specialist platforms. Valbiotis has also received an initial order 
  from the joint venture, with a view to making the first deliveries of products specifically tailored to the Asian 
  market (packaging, formulation, etc.) for Chinese consumers in the second half of 2026 (http:// 
  investisseurs.valbiotis.com/wp-content/uploads/2026/03/CP-JV-Chine-FR-OK.pdf); 
 . April 2026: The launch of e-commerce deliveries to Belgium and Luxembourg: Valbiotis is strengthening its 
  e-commerce logistics capabilities and expanding its full range of health supplements to these two markets (http:// 
  investisseurs.valbiotis.com/wp-content/uploads/2026/04/CP-Livraison-Belgique-et-Luxembourg-FR-OK.pdf); 
 . May 2026: A new phase in the Company's expansion in Asia, with the opening of a subsidiary in Singapore 
  by the joint venture owned by the Company and the AIKA Group. This establishment marks a key first step in the 
  joint venture's expansion across Asia, outside China and Hong Kong, where it is already operational. This new 
  subsidiary will gradually expand into several strategic markets across Asia, including Singapore, Vietnam, 
  Indonesia and Japan (http://investisseurs.valbiotis.com/wp-content/uploads/2026/05/CP-Singapour-Vdef.pdf). 
 . June 2026: A new milestone in the brand's expansion in the Middle East with the signing of an exclusive 
  distribution agreement with Al Danah Medical Company, a leading player in the healthcare and nutrition sector in 

(MORE TO FOLLOW) Dow Jones Newswires

June 08, 2026 02:00 ET (06:00 GMT)